Literature DB >> 8437119

Endothelial relaxing 5-hydroxytryptamine receptors in the rat jugular vein: similarity with the 5-hydroxytryptamine1C receptor.

M Bodelsson1, K Törnebrandt, B Arneklo-Nobin.   

Abstract

Serotonin (5-HT) at low concentrations induces an endothelium-dependent relaxation in the rat jugular vein mediated via a 5-HT1-like receptor. The receptor mediating this relaxation was characterized in vitro using agonists and antagonists in segments precontracted with prostaglandin F2 alpha in the presence of the 5-HT2 receptor antagonist ketanserin. The following substances acted as agonists, with the order of potency: 5-HT > dl-alpha-methyl-5-hydroxytryptamine = 5-carboxamidotryptamine > quipazine > 8-hydroxy-2-(dl-n-propylamino) tetralin. dl-Propranolol, mesulergine and mianserin acted as competitive, methysergide, 6-methyl-1-(1-methylethyl)-ergoline-8 beta-carboxylic acid 2-hydroxy-1-methylpropyl ester and sumatriptan as non-competitive, and ritanserin acted as both a competitive and non-competitive antagonist of the 5-HT-induced relaxation. Neither the 5-HT2 antagonists ketanserin and spiperone nor the 5-HT3 antagonist 1 alpha-H,3 alpha,5 alpha-H-tropan-3-yl,3,5-dichlorbenzoate affected the 5-HT-induced relaxation. The pEC50 values of the agonists and the pA2 and pAh values of the antagonists correlated strongly with pKD values at the 5-HT1C binding site. These results are consistent with a peripheral vascular 5-HT1C receptor in the rat jugular vein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437119

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Authors:  D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  5-HT2B receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells.

Authors:  C Ullmer; H G Boddeke; K Schmuck; H Lübbert
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine.

Authors:  E Glusa; A Roos
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries.

Authors:  J A Terrón; A Falcón-Neri
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

Authors:  G S Baxter; O E Murphy; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Effect of cold storage in University of Wisconsin solution on the responses of porcine hepatic arteries to 5-hydroxytryptamine and bradykinin in vitro.

Authors:  S Flanders; K J Hardy; M J Lew
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs.

Authors:  R Verheggen; S Freudenthaler; F Meyer-Dulheuer; A J Kaumann
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 8.  5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives.

Authors:  J R Fozard; H O Kalkman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

9.  In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.

Authors:  G A Kennett; M D Wood; A Glen; S Grewal; I Forbes; A Gadre; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  Study of the in vivo and in vitro cardiovascular effects of (+)-glaucine and N-carbethoxysecoglaucine in rats.

Authors:  F Orallo; A Fernández Alzueta; M Campos-Toimil; J M Calleja
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.